about
Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin.Hydroxychloroquine-related retinal toxicityFrom BILAG to BILAG-based combined lupus assessment-30 years onThe relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort studyAnti-inflammatory and immunosuppressive drugs and reproductionFactors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception CohortEfficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre studyBelimumab: a technological advance for systemic lupus erythematosus patients? Report of a systematic review and meta-analysisClinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort.Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort.Electrocardiographic findings in systemic lupus erythematosus: data from an international inception cohort.Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial).Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort.Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort.EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics.Ocular manifestations of systemic lupus erythematosus.Clinical significance of IgA anticardiolipin and anti-beta2-GP1 antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome.Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of risk (LASER) study.The role of apoptosis in systemic lupus erythematosus.The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients.Numerical scoring for the BILAG-2004 indexProspective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosusEULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs.European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studiesUpdate on systemic lupus erythematosus: autoantibodies and apoptosis.Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosusPopulation-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance programIncreased usage of special educational services by children born to mothers with systemic lupus erythematosus and antiphospholipid antibodiesPrimary anti-phospholipid antibody syndrome (APS): current concepts.Anti-C1q antibodies in systemic lupus erythematosus.Long-term complications of systemic lupus erythematosus.Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis.25-hydroxyvitamin D and cardiovascular disease in patients with systemic lupus erythematosus: data from a large international inception cohort.Tumor necrosis factor alpha activates release of B lymphocyte stimulator by neutrophils infiltrating the rheumatoid jointProstate cancer in systemic lupus erythematosusEULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis.Prevalence and predictors of fragility fractures in systemic lupus erythematosus.Non-Hodgkin's lymphoma in systemic lupus erythematosusSynovial fluid leukocyte apoptosis is inhibited in patients with very early rheumatoid arthritisDevelopment of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice.
P50
Q24817058-4CDDD586-039A-4776-8FCA-F1C8C0138B2DQ26782822-4CD395C8-14EB-4413-AAAA-54A605DAC103Q28081809-551ACC42-8227-4B29-B2B4-A1A1503286D3Q28212163-58397FDF-DCE3-49BB-85B5-8B757F2457E6Q28218219-FFCC11CA-7302-4378-9F6F-51EC42F583BBQ28608340-0ED3724C-2F03-4955-8957-5E90BF73A798Q28660706-29FAB1BE-ED0D-4022-807B-D4487D450D42Q28676968-04AD5C30-5FE6-4D75-BC45-12B2AD5E0838Q30560952-10AB7683-33C0-41D4-B8DB-2598D4D8569EQ30791606-25E24DF5-0617-47C4-88BD-114A9002C423Q30823425-F6709418-E9B9-4FAD-8C09-96460DC9C140Q30832522-DF19F518-0642-4277-B1D8-BD170D0E491CQ31122937-1B215D37-EF4A-47CD-9ACD-24836FEAA8EFQ31145074-A6097172-1869-428F-9D9C-701DA345FFE3Q33284736-7948C91E-36C5-4596-8D9F-53C78DD8AED9Q33293337-2392B515-250D-4AFA-B7BB-F35880C06B87Q33367754-D2EE209C-4A90-4909-B404-EE4ECEA8DC0AQ33517066-AEC9F4D8-5F0E-4548-9743-E9D1CD65ED68Q33787902-526FE53D-6DD1-4772-AB8C-5816408AE3FCQ33796222-DB20F319-7F6A-4CBB-9DF4-51D303489928Q34056232-C93557B7-BBB2-4E60-B536-1D6E11E49E89Q34087831-450ACB7B-28BC-4AF1-8DD7-B9AD8ACE6358Q34132211-317088F9-5AFB-4B0E-A978-DB718052D6FEQ34187282-742F7830-665B-42E7-A07D-2DE39D47AEC2Q34254073-62E0F4D7-EE92-4361-9938-4AC31F3FF1F9Q34338929-DD52F086-BBDE-4FE8-A2DA-E8F7BAD617B5Q34343779-35189EAD-2C4F-42F7-8028-271231A8AB21Q34424615-A8B5CDC9-855C-4EE2-AF41-C071BD2CF550Q34674429-883F7619-E8E8-41AD-9D54-CB2D3842D9E5Q34717540-D7649C15-AA87-4387-A6DC-937190F3B494Q34938517-E5256B54-BD44-488D-BEAA-7AB6C7E191FFQ35006892-CBA7A89E-40BF-481D-8E82-F4E4B0C5C258Q35086343-E7DC9E5F-9581-414E-B85E-82B7AF1BF431Q35094171-E7AC6AA1-B2E4-404E-99D9-1B0C47472D9AQ35464068-926B2ADC-62B5-49EA-8B91-6D3AA3BDB6CAQ35554126-5C319A0B-1EEE-4F54-98D2-73C07D645FEDQ35554619-1E2D8729-629B-42E0-8E0D-73EF680049BDQ35554851-41FC6FAF-851D-40F1-B2FD-CF066794C3E0Q35605600-E48C6C54-26CE-4D06-93CE-37FA2D24B900Q35642120-3D8C6EF8-DD24-4D9C-A1A0-EA9A001F65D2
P50
description
researcher, ORCID id # 0000-0002-1244-6443
@en
wetenschapper
@nl
name
Caroline Gordon
@ast
Caroline Gordon
@en
Caroline Gordon
@es
Caroline Gordon
@nl
type
label
Caroline Gordon
@ast
Caroline Gordon
@en
Caroline Gordon
@es
Caroline Gordon
@nl
prefLabel
Caroline Gordon
@ast
Caroline Gordon
@en
Caroline Gordon
@es
Caroline Gordon
@nl
P1006
P214
P244
P1006
P106
P1153
7401477337
P21
P214
P244
n2006183094
P31
P496
0000-0002-1244-6443
P734
P735
P7859
lccn-n2006183094